PET/CT in the management of haematological malignancies

Martin Hutchings; Lena Specht; Martin Hutchings; Lena Specht

doi:10.1111/j.1600-0609.2008.01051.x

PET/CT in the management of haematological malignancies

Martin Hutchings, Lena Specht, Martin Hutchings, Lena Specht

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

44 Citationer (Scopus)

Abstract

Positron emission tomography (PET)/computerised tomography (CT) has proved useful in a number of haematological malignancies, particularly in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphomas (NHL). It is recommended in the staging of HL and aggressive NHL, it has been shown to be prognostically important early during treatment, and it has been incorporated in the response criteria. However, treatment modification based on early scans is still experimental, and routine use in follow up cannot be recommended. The use of PET/CT in other lymphoma types and other haematological malignancies is still under evaluation.

Originalsprog	Engelsk
Bogserie	European Journal of Haematology. Supplementum
Vol/bind	80
Udgave nummer	5
Sider (fra-til)	369-80
Antal sider	12
ISSN	0902-4506
DOI	https://doi.org/10.1111/j.1600-0609.2008.01051.x https://doi.org/10.1111/j.1600-0609.2008.01051.x
Status	Udgivet - 1 maj 2008

Bibliografisk note

Keywords: Follow-Up Studies; Hematologic Neoplasms; Humans; Neoplasm Staging; Positron-Emission Tomography; Salvage Therapy; Tomography, X-Ray Computed

Adgang til dokumentet

Citationsformater

@article{e4cbbcd04c7b11df928f000ea68e967b,

title = "PET/CT in the management of haematological malignancies",

abstract = "Positron emission tomography (PET)/computerised tomography (CT) has proved useful in a number of haematological malignancies, particularly in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphomas (NHL). It is recommended in the staging of HL and aggressive NHL, it has been shown to be prognostically important early during treatment, and it has been incorporated in the response criteria. However, treatment modification based on early scans is still experimental, and routine use in follow up cannot be recommended. The use of PET/CT in other lymphoma types and other haematological malignancies is still under evaluation.",

author = "Martin Hutchings and Lena Specht and Martin Hutchings and Lena Specht",

note = "Keywords: Follow-Up Studies; Hematologic Neoplasms; Humans; Neoplasm Staging; Positron-Emission Tomography; Salvage Therapy; Tomography, X-Ray Computed",

year = "2008",

month = may,

day = "1",

doi = "10.1111/j.1600-0609.2008.01051.x",

language = "English",

volume = "80",

pages = "369--80",

journal = "European Journal of Haematology. Supplementum",

issn = "0902-4506",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - PET/CT in the management of haematological malignancies

AU - Hutchings, Martin

AU - Specht, Lena

AU - Hutchings, Martin

AU - Specht, Lena

N1 - Keywords: Follow-Up Studies; Hematologic Neoplasms; Humans; Neoplasm Staging; Positron-Emission Tomography; Salvage Therapy; Tomography, X-Ray Computed

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Positron emission tomography (PET)/computerised tomography (CT) has proved useful in a number of haematological malignancies, particularly in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphomas (NHL). It is recommended in the staging of HL and aggressive NHL, it has been shown to be prognostically important early during treatment, and it has been incorporated in the response criteria. However, treatment modification based on early scans is still experimental, and routine use in follow up cannot be recommended. The use of PET/CT in other lymphoma types and other haematological malignancies is still under evaluation.

AB - Positron emission tomography (PET)/computerised tomography (CT) has proved useful in a number of haematological malignancies, particularly in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphomas (NHL). It is recommended in the staging of HL and aggressive NHL, it has been shown to be prognostically important early during treatment, and it has been incorporated in the response criteria. However, treatment modification based on early scans is still experimental, and routine use in follow up cannot be recommended. The use of PET/CT in other lymphoma types and other haematological malignancies is still under evaluation.

U2 - 10.1111/j.1600-0609.2008.01051.x

DO - 10.1111/j.1600-0609.2008.01051.x

M3 - Journal article

C2 - 18284629

SN - 0902-4506

VL - 80

SP - 369

EP - 380

JO - European Journal of Haematology. Supplementum

JF - European Journal of Haematology. Supplementum

IS - 5

ER -